<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301596</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0409</org_study_id>
    <secondary_id>UF7840</secondary_id>
    <nct_id>NCT04301596</nct_id>
  </id_info>
  <brief_title>Assessment of Nutritional Status in Systemic Sclerosis</brief_title>
  <acronym>NUTRISCLER</acronym>
  <official_title>Assessment of Nutritional Status in Systemic Sclerosis: Prospective Cohort Study in Montpellier University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main theme of the cohort of systemic sclerosis (SSc) patients is the determination of&#xD;
      nutritional status, its evolution and the evaluation of its management in patients with&#xD;
      scleroderma.&#xD;
&#xD;
      The main objectives are :&#xD;
&#xD;
        -  To determine the incidence of malnutrition and its main determinants (disease&#xD;
           characteristics, severity, eating habits, physical activity) in patients with&#xD;
           scleroderma.&#xD;
&#xD;
        -  For patients with undernutrition at inclusion or at 18 months follow-up:&#xD;
&#xD;
      evaluate the impact of a standardized nutritional intervention (dietary advice, oral&#xD;
      supplements, artificial, enteral or parenteral nutrition) on nutritional and disease&#xD;
      parameters.&#xD;
&#xD;
      Follow-up visits will take place every 6 months for 2 years. (M6, M12, M18 et M24).&#xD;
&#xD;
      During each visit: a clinical examination, with anthropometric measurements, a 3-day dietary&#xD;
      survey and a blood sample (10 ml), completion a multiple-choice of quality of life and&#xD;
      physical activity evaluation.&#xD;
&#xD;
      Paraclinical evaluation : echocardiography, lung function tests, screening for osteoporosis&#xD;
      (M6 and M18).&#xD;
&#xD;
      If undernutrition is detected during a follow-up visit, the subject will be referred to a&#xD;
      specialized service.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Anticipated">October 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 12, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of malnutrition</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of malnutrition will be measured as a loss of more than 10% of body weight or a body mass index (BMI) less than 21 kg/m2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Idetification of risk factors associated with malnutrition</measure>
    <time_frame>6 months</time_frame>
    <description>Collection of data related to SSc disease burden</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Success of the nutritional intervention</measure>
    <time_frame>6 months</time_frame>
    <description>body weight gain &gt; 5%</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>SSc patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of data</intervention_name>
    <description>different set of data will be collected over a 6 months period</description>
    <arm_group_label>SSc patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is patients aged 18 or more with scleroderma. From preliminary data&#xD;
        obtained in our department, we can estimate that 50% of participants will meet the&#xD;
        definition of malnutrition (BMI&lt;21kg/m2 or weigh loss &gt;10% in months) at baseline.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All SSc patients aged 18 or more&#xD;
&#xD;
          -  Patient followed at the Montpellier University Hospital&#xD;
&#xD;
          -  Patients must fulfil the American College of Rheumatology (ACR) and European League&#xD;
             Against Rheumatism (EULAR) 2013 criteria for SSc.&#xD;
&#xD;
          -  Health insurance (affiliation to social security)&#xD;
&#xD;
          -  Collection of non-opposition to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under the protection of justice curatorship / guardianship;&#xD;
&#xD;
          -  Patients who have already planned to move out of the region in the next two years,&#xD;
             making the follow-up impossible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre MARIA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montpellier University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre MARIA, MD, PhD</last_name>
    <phone>+33467337332</phone>
    <email>a-maria@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe GUILPAIN</last_name>
    <email>p-guilpain@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre MARIA</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

